In parallel, phase-locked images of OH* chemiluminescence are collected and analyzed in order to determine the associated flame dynamics.
We investigated the efficacy and safety of gemcitabine, cisplatin, and sunitinib (GCS) in mUC and MIBC in parallel phase II trials.
Image analysis was done strictly in parallel: phase contrast images 2A and 2C were combined into a single.tiff file prior to image processing; and epifluorescence images B and D were combined into a single.tiff file prior to image processing.
In this study, as in the parallel phase I study of DMXAA (Jameson et al, submitted), only a single unconfirmed tumour response was seen.
In the parallel phase I study in patients with newly diagnosed brain tumours, a total of 42 patients were treated including 32 with glioblastoma multiforme (Cokgor et al, 2000).
Aflibercept efficacy in patients with newly diagnosed neovascular AMD was demonstrated in two parallel phase III trials [ 7]. Results from these trials showed that aflibercept achieves similar outcomes compared with ranibizumab and, after 3 monthly initial doses, can be administered every 2 months.
In a parallel phase III study, Intergroup N9741, oxaliplatin plus fluorouracil and leucovorin (FOLFOX) also demonstrated a survival benefit compared with IFL.
As a consequence, we have used 2 stratification factors in each parallel phase II trials: prior exposure to pazopanib and countries.
In this study, the degree of induction (22%) was less than that seen in the parallel Phase I study (69%) using the same schedule (Cropp et al, 1999; Rosen et al, 1999).
During the conduct of this trial, investigators in a parallel Phase I trial of SU5416 on the same schedule at The University of California, Los Angeles, USA reported DLT (projectile vomiting and severe headache) at 190 mg m−2 (Rosen et al, 1999).
In the parallel phase, one trial conducted by Rosen et al (1999) using the same schedule as used here, DLTs of projectile vomiting, headache and nausea, were reported at 190 mg m−2.
